Olfactory neuroblastoma: A 35‐year experience and suggested follow‐up protocol

Rimmer, Joanne; Lund, Valerie J.; Beale, Timothy; Wei, William Ignace; Howard, David

doi:10.1002/lary.24562

Cited by 104 publications

(144 citation statements)

References 34 publications

Supporting

Mentioning

128

Contrasting

Unclassified

Order By: Relevance

“…KaplanMeier analysis have shown overall and disease specific survival rates at 10 years to be 83.4 and 90 % for Kadish stage A disease, 49 and 68.3 % for those with stage B, 38.6 and 66.7 % for those with stage C, and 13.3 and 35.6 % for those with stage D [25]. In a different study, the disease free survival dropped from 221 months for Kadish A to 33 months for Kadish D cases [38]. Approximately 25 % of patients with ONB develop local recurrences and 20 % develop cervical lymph node or distant metastases [31,38].…”

Section: Prognostic Factorsmentioning

confidence: 86%

“…In a different study, the disease free survival dropped from 221 months for Kadish A to 33 months for Kadish D cases [38]. Approximately 25 % of patients with ONB develop local recurrences and 20 % develop cervical lymph node or distant metastases [31,38]. Most metastases are intracranial but spine, liver, skin, and lung metastases also occur.…”

Section: Prognostic Factorsmentioning

confidence: 97%

“…In a population-based analysis of survival and prognostic factors, Jethanamest et al [25] reported overall 5-and 10-year survival rates of 61.1 and 45.6 % respectively. In a single institution experience of 35-years, which included 95 patients with different treatment modalities, Rimmer et al [38] described overall survival rates of 83.4 and 76.1 % at 5-and 10-years with disease specific survival rates of 80 and 62.8 %, respectively. The modified Kadish staging system, Hyams histologic grade, lymph node status at presentation, treatment modality, and age have been found to be useful predictors of patient outcome and survival [25,26,31,38,39].…”

Section: Prognostic Factorsmentioning

confidence: 99%

“…In a single institution experience of 35-years, which included 95 patients with different treatment modalities, Rimmer et al [38] described overall survival rates of 83.4 and 76.1 % at 5-and 10-years with disease specific survival rates of 80 and 62.8 %, respectively. The modified Kadish staging system, Hyams histologic grade, lymph node status at presentation, treatment modality, and age have been found to be useful predictors of patient outcome and survival [25,26,31,38,39]. Hyams et al [40] introduced a four-tier histologic grading system based on architectural and cytologic parameters, and the presence of mitoses, rosettes, neurofibrillary stroma and necrosis with the better differentiated tumors being grade I and the most poorly differentiated tumors with high mitotic rate and necrosis tumors being grade IV (Table 4).…”

Section: Prognostic Factorsmentioning

confidence: 99%

“…Most metastases are intracranial but spine, liver, skin, and lung metastases also occur. Local recurrences and distant metastases can occur 10 years after initial diagnosis and treatment; therefore long term follow-up of patients affected by ONB is strongly advisable [30,38]. …”

Section: Prognostic Factorsmentioning

confidence: 99%

See 4 more Smart Citations

Neuroendocrine Neoplasms of the Sinonasal Tract: Neuroendocrine Carcinomas and Olfactory Neuroblastoma

Shah

Perez-Ordóñez

2016

Head and Neck Pathol

View full text Add to dashboard Cite

Neuroendocrine neoplasms (NENs) can occur in organs or tissues that do not contain neuroendocrine cells normally and do not necessarily imply embryologic derivation from the neuroectoderm; but rather reflect a shared phenotype characterized by the expression of multiple genes encoding both endocrine and neuronal features. NENs are rare in the sinonasal tract and are subdivided into epithelial and neural subtypes based on the presence of keratins or neurofilaments, respectively. Although relatively rare, neuroendocrine carcinomas (NECs) and olfactory neuroblastoma (ONB) are the most common neuroendocrine neoplasms of the sinonasal tract. The focus of this review is to highlight recent developments in the pathology of sinonasal NECs and ONB in light of the upcoming update of the World Health Organization (WHO) 2005 classification of tumors of the head and neck.

show abstract

Section: Prognostic Factorsmentioning

confidence: 86%

Section: Prognostic Factorsmentioning

confidence: 97%

Section: Prognostic Factorsmentioning

confidence: 99%

Section: Prognostic Factorsmentioning

confidence: 99%

Section: Prognostic Factorsmentioning

confidence: 99%

See 3 more Smart Citations

Neuroendocrine Neoplasms of the Sinonasal Tract: Neuroendocrine Carcinomas and Olfactory Neuroblastoma

Shah

Perez-Ordóñez

2016

Head and Neck Pathol

View full text Add to dashboard Cite

show abstract

Multicenter Survival Analysis and Application of an Olfactory Neuroblastoma Staging Modification Incorporating Hyams Grade

Choby

Geltzeiler

Almeida

et al. 2023

JAMA Otolaryngol Head Neck Surg

View full text Add to dashboard Cite

ImportanceCurrent olfactory neuroblastoma (ONB) staging systems inadequately delineate locally advanced tumors, do not incorporate tumor grade, and poorly estimate survival and recurrence.ObjectiveThe primary aims of this study were to (1) examine the clinical covariates associated with survival and recurrence of ONB in a modern-era multicenter cohort and (2) incorporate Hyams tumor grade into existing staging systems to assess its ability to estimate survival and recurrence.Design, Setting, and ParticipantsThis retrospective, multicenter, case-control study included patients with ONB who underwent treatment between January 1, 2005, and December 31, 2021, at 9 North American academic medical centers.InterventionStandard-of-care ONB treatment.Main Outcome and MeasuresThe main outcomes were overall survival (OS), disease-free survival (DFS), and disease-specific survival (DSS) as C statistics for model prediction.ResultsA total of 256 patients with ONB (mean [SD] age, 52.0 [15.6] years; 115 female [44.9%]; 141 male [55.1%]) were included. The 5-year rate for OS was 83.5% (95% CI, 78.3%-89.1%); for DFS, 70.8% (95% CI, 64.3%-78.0%); and for DSS, 94.1% (95% CI, 90.5%-97.8%). On multivariable analysis, age, American Joint Committee on Cancer (AJCC) stage, involvement of bilateral maxillary sinuses, and positive margins were associated with OS. Only AJCC stage was associated with DFS. Only N stage was associated with DSS. When assessing the ability of staging systems to estimate OS, the best-performing model was the novel modification of the Dulguerov system (C statistic, 0.66; 95% CI, 0.59-0.76), and the Kadish system performed most poorly (C statistic, 0.57; 95% CI, 0.50-0.63). Regarding estimation of DFS, the modified Kadish system performed most poorly (C statistic, 0.55; 95% CI, 0.51-0.66), while the novel modification of the AJCC system performed the best (C statistic, 0.70; 95% CI, 0.66-0.80). Regarding estimation of DSS, the modified Kadish system was the best-performing model (C statistic, 0.79; 95% CI, 0.70-0.94), and the unmodified Kadish performed the worst (C statistic, 0.56; 95% CI, 0.51-0.68). The ability for novel ONB staging systems to estimate disease progression across stages was also assessed. In the novel Kadish staging system, patients with stage VI disease were approximately 7 times as likely to experience disease progression as patients with stage I disease (hazard ratio [HR], 6.84; 95% CI, 1.60-29.20). Results were similar for the novel modified Kadish system (HR, 8.99; 95% CI, 1.62-49.85) and the novel Dulguerov system (HR, 6.86; 95% CI, 2.74-17.18).Conclusions and RelevanceThe study findings indicate that 5-year OS for ONB is favorable and that incorporation of Hyams grade into traditional ONB staging systems is associated with improved estimation of disease progression.

show abstract

ICAR: endoscopic skull‐base surgery

Wang

Zanation

Gardner

et al. 2019

Int Forum Allergy Rhinol

Self Cite

157

279

View full text Add to dashboard Cite

Background Endoscopic skull‐base surgery (ESBS) is employed in the management of diverse skull‐base pathologies. Paralleling the increased utilization of ESBS, the literature in this field has expanded rapidly. However, the rarity of these diseases, the inherent challenges of surgical studies, and the continued learning curve in ESBS have resulted in significant variability in the quality of the literature. To consolidate and critically appraise the available literature, experts in skull‐base surgery have produced the International Consensus Statement on Endoscopic Skull‐Base Surgery (ICAR:ESBS). Methods Using previously described methodology, topics spanning the breadth of ESBS were identified and assigned a literature review, evidence‐based review or evidence‐based review with recommendations format. Subsequently, each topic was written and then reviewed by skull‐base surgeons in both neurosurgery and otolaryngology. Following this iterative review process, the ICAR:ESBS document was synthesized and reviewed by all authors for consensus. Results The ICAR:ESBS document addresses the role of ESBS in primary cerebrospinal fluid (CSF) rhinorrhea, intradural tumors, benign skull‐base and orbital pathology, sinonasal malignancies, and clival lesions. Additionally, specific challenges in ESBS including endoscopic reconstruction and complication management were evaluated. Conclusion A critical review of the literature in ESBS demonstrates at least the equivalency of ESBS with alternative approaches in pathologies such as CSF rhinorrhea and pituitary adenoma as well as improved reconstructive techniques in reducing CSF leaks. Evidence‐based recommendations are limited in other pathologies and these significant knowledge gaps call upon the skull‐base community to embrace these opportunities and collaboratively address these shortcomings.

show abstract

Olfactory neuroblastoma: A 35‐year experience and suggested follow‐up protocol

Abstract: 4.

Cited by 104 publications

References 34 publications

Neuroendocrine Neoplasms of the Sinonasal Tract: Neuroendocrine Carcinomas and Olfactory Neuroblastoma

Neuroendocrine Neoplasms of the Sinonasal Tract: Neuroendocrine Carcinomas and Olfactory Neuroblastoma

Multicenter Survival Analysis and Application of an Olfactory Neuroblastoma Staging Modification Incorporating Hyams Grade

ICAR: endoscopic skull‐base surgery

Contact Info

Product

Resources

About